Single-chain chimeric polypeptide claims and compositional claims for lead product candidate HCW9302
MIRAMAR, Fla., Aug. 3, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”) NASDAQ: HCWB) is a clinical-stage biopharmaceutical company that transforms immunotherapies to improve healthy life expectancy. We are focused on the discovery and development of novel immunotherapies that prolong The relationship between chronic low-grade inflammation and age-related diseases was granted in US Patent No. 11,401,324. The patent contains claims to an immunotherapeutic compound consisting of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made from human tissue extracellular domains. element.
This patent provides intellectual property protection for the lead drug candidate, HCW9302. HCW9302 has controllability T (“Tregister“) Cells with inflammasomes and cells that suppress the activity of the inflammatory factors they secrete.register We support the potential of HCW9302 to treat various autoimmune and pro-inflammatory diseases. HCW9302 is currently completing his IND compliance activities for his IND submission for autoimmune disease clinical trials.
HCW Biologics has developed novel single- and multi-chain chimeric polypeptides and methods of using these polypeptides alone and in combination.
Hing C. Wong, Ph.D., Hing C. Wong, Ph.D., Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, said: I expressed my excitement that I had arrived. Issuing the first patent is a significant step in the evolution of our patent portfolio. This news, along with progress in the prosecution of our other patent applications, indicates that our new single- and multi-chain immunotherapies are novel, as are the proprietary approaches used to create them on the TOBI™ discovery platform. Reinforcing our belief that there is , a valuable asset. We are pleased to announce that this patent has been granted by the US Patent and Trademark Office. This provides significant recognition and protection for the intellectual property underlying one of his lead product candidates, the HCW9302. ”
HCW Biologics is represented by Fish & Richardson PC, one of the world’s leading intellectual property law firms. Tiffany A. Reiter, Ph.D., Principal, Boston Office, Fish & Richardson PC, said:
About HCW Biologics:
HCW Biologics discovers and develops novel immunotherapies to extend healthy life expectancy by breaking the link between chronic low-grade inflammatory and age-related diseases such as cancer, cardiovascular disease, diabetes and neurodegenerative diseases A clinical-stage biopharmaceutical company focused on autoimmune disease. We have combined our deep understanding of disease-related immunology with advanced protein engineering expertise to develop the TOBI™ (Tissue Fact-Based Fusion) discovery platform. We use our TOBI™ discovery platform to generate designer novel multifunctional fusion molecules with immunotherapeutic properties. The invention of his two lead molecules at HCW Biologics, his HCW9218 and his HCW9302, were made via the TOBI™ discovery platform. The Masonic Cancer Center at the University of Minnesota has initiated a phase 1 clinical trial evaluating his HCW9218 in solid tumors that have progressed after previous chemotherapy. The FDA also approved HCW Biologics to initiate a Phase 1b clinical trial of his HCW9218 in patients with advanced pancreatic cancer. HCW9302 is currently undergoing his IND-ready trial for autoimmune indications.
Forward-Looking Statements:
Statements in this press release contain “forward-looking statements” that involve significant risks and uncertainties. These statements are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. “believe”, “will”, “may”, “should”, “estimate”, “predict”, “prospect”, “predict” or other similar words, HCW Biologics issued patents or other intellectual property. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. In addition, certain forward-looking statements are based on assumptions regarding future events that may not prove to be accurate. Factors that could cause actual results to differ include the risks and uncertainties described in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission. including but not limited to gender. (“SEC”), in its annual report on Form 10-K filed with the SEC on March 29, 2022 and in other filings filed with the SEC from time to time. The forward-looking statements contained in this press release are made as of this date, and the Company does not undertake any obligation to update such information, except as required by applicable law.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
Comments
Post a Comment